Ultimovacs ASA
OSE:ULTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ultimovacs ASA
Selling, General & Administrative
Ultimovacs ASA
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
U
|
Ultimovacs ASA
OSE:ULTI
|
Selling, General & Administrative
-kr40.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Selling, General & Administrative
-kr22.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Selling, General & Administrative
-kr67.9m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Selling, General & Administrative
-$13.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Selling, General & Administrative
-kr10.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Selling, General & Administrative
-kr50.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-10%
|
|
Ultimovacs ASA
Glance View
Ultimovacs AS operates as a pharmaceutical company. The company is headquartered in Oslo, Oslo. The company went IPO on 2019-06-03. The firm's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The firm is performing a broad clinical development program with clinical trials in Europe and the USA.
See Also
What is Ultimovacs ASA's Selling, General & Administrative?
Selling, General & Administrative
-40.5m
NOK
Based on the financial report for Dec 31, 2024, Ultimovacs ASA's Selling, General & Administrative amounts to -40.5m NOK.
What is Ultimovacs ASA's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-12%
Over the last year, the Selling, General & Administrative growth was 49%. The average annual Selling, General & Administrative growth rates for Ultimovacs ASA have been 15% over the past three years , -12% over the past five years .
